Scalable single-molecule chromatin accessibility profiling in immune cells
Official title: Scalable, single-molecule and single-cell chromatin accessibility profiling in primary immune cells
Funded at Epicypher, INC. · NIH-11313171 · Data updated 2026-11-12
A new approach aims to map which parts of the genome are accessible and which proteins bind them in immune cells, using advanced sequencing on a scale that could reveal detailed cell-by-cell information.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Epicypher, INC. NIH-funded |
| Lab location | 1 site (Research Triangle Park, UNITED STATES) |
| Project start | August 21, 2026 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $999,268 |
| NIH project number | 1R44AI197362-01 |
| Project ID | NIH-11313171 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with immune-related conditions or diseases where immune cell regulation is relevant may benefit from improved diagnostics and therapies in the long term.
✕Less likely to help
Healthy individuals without immune-related conditions may have indirect benefits through advances in basic science and future applications.
What this research studies
This project develops methods to profile chromatin accessibility in immune cells at the level of single molecules and single cells, using long-read sequencing to preserve context. By partnering with experts, it seeks to enable haplotype-specific insights and better understanding of how immune cells develop and respond. The research focuses on creating amplification-friendly long-read methods to study rare cell populations and complex tissues like lymph nodes, with the goal of enabling more precise epigenomic maps. If successful, these tools could help researchers uncover how regulatory elements control immune cell behavior in health and disease.
Why it matters
Potential benefit: If successful, patients could benefit from more precise understanding of immune cell regulation, potentially informing personalized approaches to immune-related diseases.
How similar studies have gone: Previous chromatin accessibility studies have shown value, and long-read approaches are an emerging area with promising early results.
Where this research is happening
-
Epicypher, INC.
Research Triangle Park, United States Active
Researchers
- Principal investigator: Venters, Bryan J — Epicypher, INC.
- Study coordinator: Venters, Bryan J
Related research
Other NIH-funded projects on the same topics.
-
New tools to map and measure epigenetic changes in aging and Alzheimer's disease
A small grant is funding new methods to find and measure combinations of chemical tags on histones that change with aging and Alzheimer’s disease, helping identify targets and biomarkers.
-
Mapping how drugs bind to chromatin to speed new therapies
A new test will map where small drug molecules touch chromatin in human cells to help design better, safer epigenetic drugs.
-
New tools to study how asymmetric histone tweaks control gene activity
A new NIH grant aims to create designer nucleosomes with asymmetric modifications to better understand how gene regulation is influenced by the histone code, which could lead to better biomarkers and therapies for cancer.
-
Epigenomic profiling of cell-free nucleosomes in plasma cancer research
A new test platform analyzes the tiny pieces of DNA wrapped around proteins in blood to help identify cancer signals.
-
A New Way to Map DNA Structures Linked to Alzheimer's and Aging
This project is creating a new and more accurate way to map special DNA structures called R-loops, which are connected to aging and brain diseases like Alzheimer's.
-
A new blood test for cancer detection
This project is developing a new type of blood test to find cancer more accurately by looking at specific markers in your blood.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.